The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
Open accessAbstract
We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview of corresponding technologies is given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“therapy) liquid biopsy may allow longitudinal disease surveillance to monitor developing tumor heterogeneity [5].”
BackgroundDetection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · cited 1×
“for detection of minimal residual disease [59, 60].”
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492 · cited 1×
“In general, the amount of circulating tumor DNA (ctDNA) increases with tumor burden sums up to 1% of total ccfDNA in early-stage disease and up to 40% in late-stage disease [47] and ctDNA allows detection of a relapse relative early [48, 49].”
BackgroundKrebs, M. G., Hou, J.-M., Sloane, R., Lancashire, L., Priest, L., Nonaka, D., Ward, T. H., Backen, A., Clack, G., Hughes, A., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823c5c16 · Cited by 463
Cited by
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Life and death of circulating cell-free DNA
Kustanovich, A., Schwartz, R., Peretz, T., & Grinshpun, A. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1598759 · Cited by 606
Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis
De Rubis, G., Rajeev Krishnan, S., & Bebawy, M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.006 · Cited by 535
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
RetractedRecent advances in gastric cancer early diagnosis
Necula, L., Matei, L., Dragu, D., Neagu, A. I., Mambet, C., Nedeianu, S., Bleotu, C., Diaconu, C. C., & Chivu-Economescu, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i17.2029 · Cited by 435
Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases
Duvvuri, B., & Lood, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00502 · Cited by 282
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Stejskal, P., Goodarzi, H., Srovnal, J., Hajdúch, M., van ’t Veer, L. J., & Magbanua, M. J. M. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01710-w · Cited by 278
Zhou, H., Zhu, L., Song, J., Wang, G., Li, P., Li, W., Luo, P., Sun, X., Wu, J., Liu, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01556-2 · Cited by 261
Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment
Choukaife, H., Seyam, S., Alallam, B., Doolaanea, A. A., & Alfatama, M. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s375229 · Cited by 127
“As a result, the concept “liquid biopsy” has been widely known and is now utilised to detect all circulating tumour features, primarily ctDNA, CTCs, circulating miRNAs, as well as others such mRNAs, exosomes, proteins, and others) in peripheral blood or other biological fluids.(58) In the context of multiple clinical…”
BackgroundNetwork approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
Metadata
- Authors
- Neumann, M. H. D., Bender, S., Krahn, T., & Schlange, T.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2018
- Volume
- 16
- Pages
- 190-195
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W2807613611
- Cited by
- 204
- References
- 6
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.